Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours
Status:
Completed
Trial end date:
2019-01-10
Target enrollment:
Participant gender:
Summary
The study evaluates the safety and activity of NOX66 in patients with refractory solid tumors
that are non responsive to standard therapies.
This is a two part with a potential third part, open-label, multicenter, dose escalation
study of NOX66 as monotherapy and in combination with carboplatin.